Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved tafasitamab (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
Efficacy was evaluated in inMIND, a double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04680052) randomizing 548 patients with relapsed or refractory FL to receive tafasitamab or placebo with lenalidomide and rituximab.